Chemical exchange saturation transfer MRI to assess cell death in breast cancer xenografts at 7T

Jonathan Klein, Wilfred W. Lam, Gregory J. Czarnota, Greg J. Stanisz

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Purpose: Detecting cell death and predicting tumor response early in a course of chemotherapy could help optimize treatment regimens and improve clinical outcomes. Chemical exchange saturation transfer (CEST) MRI was investigated in vivo to study properties that may be able to detect cancer death. Results: Using a magnetization transfer ratio (MTR) cutoff of 0.12 at 1.8 ppm was able to differentiate between viable tumor and cell death regions. Comparison of MTR values at this frequency showed significant differences (p < 0.0001) between viable tumor and cell death regions, matching patterns seen on histology. Using this cutoff, the mean increase in cell death index (± standard error of the mean) after chemotherapy was 4 ± 4%, 10% ± 7%, 10 ± 8%, and 4 ± 9% at 4, 8, 12, and 24 h, respectively. Conclusions: CEST MRI can detect cell death in MDA-231 xenografts but further work is needed to characterize the clinical applications of this finding. Maximum response to chemotherapy occurred at 8-12 h after chemotherapy injection in this in vivo tumor model. Materials and Methods: Breast cancer xenografts (MDA-MB-231) were scanned using 7 T MRI before and after chemotherapy. As a measure of CEST effect at 0.5 μT saturation amplitude, MTR values at frequency offsets of 1.8 and -3.3 ppm were evaluated. CEST signals after chemotherapy treatment were compared to celldeath histopathology of tumors.

Original languageEnglish (US)
Pages (from-to)31490-31501
Number of pages12
JournalOncotarget
Volume9
Issue number59
DOIs
StatePublished - Jul 31 2018

Keywords

  • Breast cancer
  • CEST
  • Cell death
  • MRI
  • Response monitoring

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Chemical exchange saturation transfer MRI to assess cell death in breast cancer xenografts at 7T'. Together they form a unique fingerprint.

  • Cite this